The effect of astemizole on exercise-induced asthma.
Astemizole, a new oral long acting antihistamine devoid of significant central, sedative or anticholinergic effects, was studied in nine patients with exercise-induced asthma. Most patients received some protection with the active drug after 1 week of treatment (10 mg daily) and all showed less of a fall in FEV1 on exercise 1 week after stopping the drug compared with an initial placebo period (P less than 0.01). A significant reduction in histamine-induced skin reaction (weal size) was also demonstrated (P less than 0.01).
D000328:Adult; D016589:Astemizole; D001249:Asthma / Q000188:drug therapy*; D001250:Asthma, Exercise-Induced / Q000188:drug therapy*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D005541:Forced Expiratory Volume; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D012882:Skin Tests
D001562:Benzimidazoles; D006634:Histamine H1 Antagonists; D016589:Astemizole